Amber Implants commenced clinical trials for the VCFix Spinal System. This first-in-human clinical trial will assess the safety and effectiveness of VCFix for patients with vertebral compression fractures. The implant is provided with a user-friendly single-use sterile surgical kit, ensuring traceability and reducing the risk of infection.
The VCFix Spinal System offers a strategy for managing a diverse range of vertebral fractures, and can eliminate the need for bone cement while ensuring continued compatibility. This system is designed to be applicable for both single- and multi-level posterior fixation and is engineered for enhanced mechanical strength, maximum fracture reduction,and anatomical restoration.
VCFix was granted Breakthrough Device Designation in 2021 and also received support by means of a $10 million Series A Financing in the same year.
Source: Amber Implants
Amber Implants commenced clinical trials for the VCFix Spinal System. This first-in-human clinical trial will assess the safety and effectiveness of VCFix for patients with vertebral compression fractures. The implant is provided with a user-friendly single-use sterile surgical kit, ensuring traceability and reducing the risk of infection.
The...
Amber Implants commenced clinical trials for the VCFix Spinal System. This first-in-human clinical trial will assess the safety and effectiveness of VCFix for patients with vertebral compression fractures. The implant is provided with a user-friendly single-use sterile surgical kit, ensuring traceability and reducing the risk of infection.
The VCFix Spinal System offers a strategy for managing a diverse range of vertebral fractures, and can eliminate the need for bone cement while ensuring continued compatibility. This system is designed to be applicable for both single- and multi-level posterior fixation and is engineered for enhanced mechanical strength, maximum fracture reduction,and anatomical restoration.
VCFix was granted Breakthrough Device Designation in 2021 and also received support by means of a $10 million Series A Financing in the same year.
Source: Amber Implants
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.